[1] |
Taylor J R, Dietrich E, Powell J G. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity[J]. Clin Ther, 2013, 35(1):A3-A17.
|
[2] |
Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities[J]. Diabetes Obes Metab, 2015, 17(11):1021-1032.
|
[3] |
Ibrahim M M. Subcutaneous and visceral adipose tissue:structural and functional differences[J]. Obes Rev, 2010,11(1):11-18.
|
[4] |
Rodríguez-López C P, González-Torres M C, Cruz-Bautista I, et al. Visceral obesity, skeletal muscle mass and resistin in metabolic syndrome development[J]. Nutr Hosp, 2019, 36(1):43-50.
|
[5] |
Ponti F, Santoro A, Mercatelli D, et al. Aging and imaging assessment of body composition:from fat to facts[J]. Front Endocrinol (Lausanne), 2020,10:861.
|
[6] |
Harlow S D, Gass M, Hall J E, et al. Executive summary of the stages of reproductive aging workshop +10:addressing the unfinished agenda of staging reproductive aging[J]. J Clin Endocrinol Metab, 2012,97(4):1159-1168.
|
[7] |
Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan[J]. Circ J, 2002, 66(11):987-992.
|
[8] |
Wajchenberg B L. Subcutaneous and visceral adipose tissue:their relation to the metabolic syndrome[J]. Endocr Rev, 2000, 21(6):697-738.
|
[9] |
Neeland I J, Ross R, Després J P, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease:a position statement[J]. Lancet Diabetes Endocrinol, 2019, 7(9):715-725.
|
[10] |
González N, Moreno-Villegas Z, González-Bris A, et al. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes[J]. Cardiovasc Diabetol, 2017,16(1):44.
|
[11] |
Liu L, Feng J, Zhang G, et al. Visceral adipose tissue is more strongly associated with insulin resistance than subcutaneous adipose tissue in Chinese subjects with pre-diabetes[J]. Curr Med Res Opin, 2018, 34(1):123-129.
|
[12] |
Smith U, Kahn B B. Adipose tissue regulates insulin sensitivity:role of adipogenesis, de novo lipogenesis and novel lipids[J]. J Intern Med, 2016, 280(5):465-475.
|
[13] |
王冉,李晓南. 人体脂肪组织部位差异性与代谢综合征[J]. 生理学报, 2017, 69(3):357-365.
|
[14] |
Boersma G J, Johansson E, Pereira M J, et al. Altered glucose uptake in muscle, visceral adipose tissue, and brain predict whole-body insulin resistance and may contribute to the development of type 2 diabetes:a combined PET/MR study[J]. Horm Metab Res, 2018,50(8):627-639.
|
[15] |
王丹彤,彭定琼.腹部脂肪组织分布与2型糖尿病患者胰岛素抵抗的相关性研究[J]. 中国糖尿病杂志,2015,23(7):587-589.
|
[16] |
Neeland I J, Turer A T, Ayers C R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults[J]. JAMA, 2012, 308(11):1150-1159.
|
[17] |
Tang L, Zhang F, Tong N.The association of visceral adipose tissue and subcutaneous adipose tissue with metabolic risk factors in a large population of Chinese adults[J]. Clin Endocrinol (Oxf), 2016, 85(1):46-53.
|
[18] |
Hwang Y C, Fujimoto W Y, Hayashi T, et al. Increased visceral adipose tissue is an independent predictor for future development of atherogenic dyslipidemia[J]. J Clin Endocrinol Metab, 2016,101(2):678-685.
|
[19] |
Gruzdeva O, Borodkina D, Uchasova E, et al. Localization of fat depots and cardiovascular risk[J]. Lipids Health Dis, 2018,17(1):218.
|
[20] |
Wedell-Neergaard A S, Lang Lehrskov L, Christensen R H, et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling:a randomized controlled trial[J]. Cell Metab,2019,29(4):844-855.
|
[21] |
Dye L, Boyle N B, Champ C, et al. The relationship between obesity and cognitive health and decline[J]. Proc Nutr Soc, 2017,76(4):443-454.
|
[22] |
Bendall C L, Mayr H L, Opie R S, et al. Central obesity and the mediterranean diet:a systematic review of intervention trials[J]. Crit Rev Food Sci Nutr, 2018,58(18):3070-3084.
|